Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiology and Therapeutics

Yu-Sheng Li; Qing Liu; Jian Tian; Hong-Bo He; Wei Luo

doi:10.1016/j.amjms.2018.12.004

Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiology and Therapeutics

Am J Med Sci. 2019 Apr;357(4):280-288. doi: 10.1016/j.amjms.2018.12.004. Epub 2018 Dec 13.

Authors

Yu-Sheng Li¹, Qing Liu¹, Jian Tian¹, Hong-Bo He¹, Wei Luo²

Affiliations

¹ Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
² Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China. Electronic address: luoweixy@csu.edu.cn.

PMID: 30711189
DOI: 10.1016/j.amjms.2018.12.004

Abstract

In this review, we discuss the pathologic mechanism of the angiogenesis process in osteosarcoma (OS) and the therapeutic use of angiogenesis inhibitors in OS treatment. The activation of endothelial cells by angiogenic factors leads to the production of proteolytic enzymes, which degrade the extracellular matrix. The degradation of the underlying basement membrane enables endothelial cells to proliferate and migrate to the surrounding tissue to form new vessels. These new vessels provide cancer cells with oxygen and nutrition and play an important role in cancer cell survival and metastasis. Thus, antiangiogenic therapies might be an interesting approach in OS therapeutics.

Keywords: Angiogenesis; Angiogenesis inhibitors; Growth factors; Osteosarcoma.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Humans
Neovascularization, Pathologic* / physiopathology
Neovascularization, Pathologic* / therapy
Osteosarcoma* / physiopathology
Osteosarcoma* / therapy

Substances

Angiogenesis Inhibitors